Network-guided modeling allows tumor-type independent prediction of sensitivity to all- trans -retinoic acid

Conclusions</div>In summary, we generated a tumor-type independent ATRA-sensitivity predictor which consists of a restricted number of genes and has the potential to be applied in the clinics. Identification of the tumor types that are likely to be generally sensitive to the action of ATRA paves the way to the design of clinical studies in the context of these diseases. In addition, <span style="font-style:italic;">ATRA-21</span> may represent an important diagnostic tool for the selection of individual patients who may benefit from ATRA-based therapeutic strategies also in tumors characterized by lower average sensitivity.</span>
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research